A Study to Compare Golcadomide and Rituximab vs Investigator's Choice in Follicular Lymphoma
Phase 3
400
about 5 years
18+
31 sites in AK, AL, AR +14
Why this study is shown
What this study is about
Researchers are testing whether golcadomide combined with rituximab is more effective than a treatment chosen by the doctors (investigator's choice) for people whose follicular lymphoma has returned after other treatments. The trial will last about 1829 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Bendamustine
- 2.Take Cyclophosphamide
- 3.Take Doxorubicin
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bendamustine, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), prednisolone, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
infusion, oral (Oral Capsule), oral (Disintegrating Oral Tablet), oral
Primary: Progression free survival (PFS) assessed by Independent Review Adjudication committee (IRAC)
Secondary: Duration of Response (DoR), Event free survival (EFS), Minimal residual disease (MRD) negativity, ORR as assessed by investigator, Overall response rate (ORR) assessed by IRAC, Overall survival (OS), PFS as assessed by investigator, PFS on next anti-lymphoma treatment (PFS2)
Oncology